A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells-Reference-Cited by-同舟云学术

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Published:2012-09-30 Issue:11 Volume:8 Page:890-896
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Knutson Sarah K,Wigle Tim J,Warholic Natalie M,Sneeringer Christopher J,Allain Christina J,Klaus Christine R,Sacks Joelle D,Raimondi Alejandra,Majer Christina R,Song Jeffrey,Scott Margaret Porter,Jin Lei,Smith Jesse J,Olhava Edward J,Chesworth Richard,Moyer Mikel P,Richon Victoria M,Copeland Robert A,Keilhack Heike,Pollock Roy M,Kuntz Kevin W

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/nchembio.1084.pdf

Reference47 articles.

1. Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P. & Reinberg, D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16, 2893–2905 (2002).

2. Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039–1043 (2002).

3. Agger, K. et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731–734 (2007).

4. Hong, S. et al. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl. Acad. Sci. USA 104, 18439–18444 (2007).

5. Lee, M.G. et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318, 447–450 (2007).

Cited by 680 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors;Journal of Biological Chemistry;2024-09

2. EZH2 represses mesenchymal genes and upholds the epithelial state of breast carcinoma cells;Cell Death & Disease;2024-08-22

3. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry;Future Medicinal Chemistry;2024-07-31

4. Advances in biology, diagnosis and treatment of DLBCL;Annals of Hematology;2024-07-17

5. Chromatin remodellers as therapeutic targets;Nature Reviews Drug Discovery;2024-07-16